Gynecologic Cancer

The information below is intended for use by health care providers only. Please consult with your health care provider for more information about clinical trials.

A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001 / ENGOT-ov43)

The purpose of this study is to assess the efficacy and safety of treatment with carboplatin/paclitaxel PLUS pembrolizumab (MK-3475) and maintenance olaparib (MK-7339) in women with epithelial ovarian cancer (EOC), fallopian tube cancer, or primary peritoneal cancer.

Study Details

  • Study Site/Tumor Location: Gynecologic Cancer
  • Study Location: Miami Valley Hospital South Campus
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Female
  • Principal Investigator: Dr. Michael Guy
  • Other Physicians who can consent: Dr. Guy, Dr. Reid, Dr. Ore

Study Contact Information